CA-BEHAVIOSEC
21.4.2021 09:02:13 CEST | Business Wire | Press release
BehavioSec , the industry pioneer and technology leader for behavioral biometrics and continuous authentication, today announced new findings that organizations and consumers can feel more comfortable with wider use of behavioral biometrics to safeguard their online digital experiences and identities.
Following a year of digital transformation on a societal level, the demand for better online user experience and a stronger level of digital identity protection has become essential. With a year when the world has seen a combination of personal data theft with new rulings and proposed legislation, like the EU Schrems II in July 2020 and the US National Biometrics Information Privacy Act in August [US Senators Merkley, D-OR and Sanders, I-VT], the need for expert guidance has never been higher. BehavioSec shares this research and a company milestone to highlight how behavioral biometrics can be adopted transparently with clear benefits, and in compliant fashion with comprehensive data protection laws. These include measures like the European General Data Protection Regulation (GDPR), the European Commission’s PSD2/SCA and its Open Banking mandate, the US California Consumer Privacy Act (CCPA) and similar, anticipated requirements of regulations proposed in other regions.
To validate the safe use of behavioral biometrics at a time when headlines are full of allegations about technologies like facial recognition and “deep fake” simulations being abused, BehavioSec sponsored the report, “2021 Global Data Privacy Regulation of Physical & Behavioral Biometrics” by respected industry research firm Goode Intelligence . In the report, Chief Analyst Alan Goode dives into the relevance of current and proposed global privacy and data protection legislation on the successful and compliant adoption of biometrics technology for authentication and identity verification, and addresses the key questions organizations and consumers are asking:
- Where do the next wave of behavioral-based technologies fit?
- How do they impact our delicate balance between security, privacy, and regulation?
- Are they covered under existing and proposed regulation?
- Will behavior-based technology make matters worse - or much better?
Leveraging global bank customer input, extensive research, and legal opinion from attorneys at international law firm Osborne Clarke , the paper outlines how enterprises can confidently use behavioral biometrics while complying with some of the strictest privacy and data protection laws in the world, including GDPR, industry payment regulations like PSD2 SCA, and 3D Secure 2.0 technology.
“As we move more of our personal and business tasks online, it is becoming increasingly important to secure digital channels,” says Goode. “Mobile security is more important than ever before and behavioral biometric technology has proven itself as a vital tool in enabling secure access to digital services, preventing fraudsters from gaining access, all while remaining compliant to GDPR, among others.”
A US-based webcast, “Biometrics & Digital Identity Verification – 2021 Data Protection & Privacy Regulation Insights” will be broadcast on May 25, 2021 featuring a presentation by Alan Goode on his report’s findings and offer further insight on data privacy, digital transformation and fighting fraud and cybercrime using biometrics. Viewers can register to watch the webinar hosted by BehavioSec and IDG including a discussion between CSO’s Bob Bragdon, Alan Goode and an expert panel including Dr. Shane Shook, Financial Crimes Investigator and Venture Consultant at ForgePoint Capital, Jordan Blake, BehavioSec Vice President of Products, and Jake Bernstein J.D., attorney at Focal PLLC and former Washington State Assistant Attorney General.
“It is crucial to proactively stir these debates now on how new technologies define identity and authentication, before assumptions and lack of transparency – even if unintended – irrevocably shake public and policymakers’ trust,” added Jake Bernstein, who specialized in prosecuting consumer protection cases during his time in the U.S. Washington State Attorney General’s office. “The boundary between improving digital trust and triggering privacy and identity crises does not have to be a slippery slope where biometric-based systems are concerned. Yet, perceived missteps and alleged abuse of facial-recognition and other innovations to-date show us what stakeholders, including businesses, have to avoid.”
Additionally, on May 26th at 3:00pm BST/4:00pm CEST, Goode will host a second webcast, “2021 Global Regulation of Physical & Behavioral Biometrics for Digital Identity Verification” , to present his research on the impacts of privacy and data protection regulation on the implementation of biometrics by businesses, particularly across the European Union. As the Founder, CEO, and Chief Analyst of Goode Intelligence, Goode is a respected expert in information security and biometrics and will offer insights on how businesses may be able to consider their specific use cases and possible exceptions for explicit consent according to GDPR regulation. Goode will be joined by BehavioSec and international law firm Osborne Clarke, who BehavioSec commissioned to advise on the regulatory impact to customer deployments of the BehavioSec behavioral biometrics platform , specifically within the German banking sector.
“There’s no question that technology vendors need to continue to work collaboratively with government and business to ensure better protection and experience for consumers and employees while staying fully compliant,” said BehavioSec CEO Neil Costigan. “As the pioneer in this space, we’re offering this research to the market to open the dialogue, and we’re also demonstrating and modeling compliance as a company. Beyond our ongoing support of GDPR and security best practices, we are happy to share our recent SOC2 Type1 certification and our active program for Type 2 and ISO 27001.”
To access this research, the public can download Alan Goode’s report and join the public webcasts with CSO [IDG] in the US on May 25th and with Goode Intelligence in Europe on May 26th .
About BehavioSec
BehavioSec is the industry pioneer and technology leader for behavioral biometrics and continuous authentication, safeguarding millions of users and billions of transactions today.
Deployed across Global 2000 companies to dramatically reduce fraud, friction, threat, and theft, BehavioSec verifies and protects human digital identities by understanding how we uniquely type and swipe across our ever-changing devices. Whether used in the Cloud or on-premises, BehavioSec delivers the superior user experience, precision, and scale needed by organizations to keep customers engaged while catching evasive, real-time attacks other solutions miss.
Founded in the Nordics in 2008 out of groundbreaking research, industry-recognized BehavioSec partners with market leaders and organizations like DARPA, and has earned investment from top investment firms like ForgePoint Capital, Cisco, ABN AMRO, Conor Ventures, and Octopus Ventures. Headquartered in San Francisco, CA with offices worldwide, BehavioSec is ready to help you reduce risk, improve compliance, and digitally transform your distributed workforce and customer experience. www.behaviosec.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210421005101/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press release
Potential first-in-class GPC3 x 4-1BB bispecific achieves a 36% confirmed response rate at Phase 3 dose and favorable safety profile in heavily pretreated liver cancerBrain-penetrant PRMT5 inhibitor shows promising antitumor and CNS activity in the largest publicly shared MTAP-deficient datasetFirst clinical data of CEA-targeting ADC demonstrates encouraging and sustained responses in CEAhigh NSCLC BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to dise
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
